Shots:
- Celltrion announced that Steqeyma (ustekinumab-stba), a biosimilar to Stelara, has been added to the Costco Member Prescription Program. It was launched on Mar 12, 2025. Celltrion’s adalimumab-aaty was added to the program in Aug 2024
- Steqeyma will be available in the US from Costco Specialty Pharmacies on Apr 1, 2025, for self-funded employer plans, uninsured Costco members paying cash, or those denied insurance coverage
- Steqeyma, a human IL-12 & IL-23 antagonist, is available as SC injection (45mg/0.5mL or 90mg/1mL in a single-dose, prefilled syringes) & IV infusion (130mg/26mL solution in a single-dose vial) for the treatment of PsO & PsA in adult & pediatric patients, as well as for CD and UC adult patients
Ref: PRNewswire | Image: Celltrion | Press Release
Related News:- Celltrion launches SteQeyma (Biosimilar, Stelara) in the US
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
